2019 Fiscal Year Final Research Report
Development of vaccine therapy for prevention of diabetic retinopathy
| Project/Area Number |
19K21358
|
|---|
| Project/Area Number (Other) |
18H06266 (2018)
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund (2019)
Single-year Grants (2018) |
|---|
| Review Section |
0906:Surgery related to the biological and sensory functions and related fields
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-08-24 – 2020-03-31
|
| Keywords | ワクチン / 糖尿病網膜症 / 眼疾患 / プロレニン |
|---|
| Outline of Final Research Achievements |
Vaccine therapy has been viewed one of the most successful treatments in the history. In fact, vaccine therapy has saved thousands of lives from life-threatening infectious diseases so far. Nowadays, vaccine is expected to be used for non-infectious diseases such as hypertension, diabetes, Alzheimer's disease, cancer and autoimmune diseases. In our study, we tried to optimize vaccine therapy for diabetic retinopathy by targeting prorenin. Prorenin is the most upstream protein in the renin-angiotensin system and plays a crucial role in the development of diabetic retinopathy. We succeeded in optimizing prorenin peptide vaccine and tested the effect of prorenin peptide vaccine in type 2 diabetes murine model. Our data demonstrate prorenin peptide vaccine prevented neuronal dysfunction and inflammation in the retina. Now we are planning to investigate the precise mechanism of beneficial effect of prorenin peptide vaccine by using porcine model of type 2 diabetes.
|
| Free Research Field |
眼科学
|
| Academic Significance and Societal Importance of the Research Achievements |
全世界で糖尿病患者数が増加しており、一種のパンデミックとなっている。そのため糖尿病網膜症による失明が増加し、結果として労働者人口が減少、医療費の増大がより深刻化する可能性がある。一方で進行した糖尿病網膜症に対して抗VEGF療法が適応されるが、非常に高価であることが問題となっている。治療ワクチンの特徴は、比較的安価、幅広い疾患に適応が可能であることが挙げられる。もし治療ワクチンが糖尿病網膜症へ応用されれば、医療費の増大を抑制しつつ、より多くの人々を糖尿病による失明から救うことが出来る。
|
